Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.
		
    Metabolic health and cardiometabolic risk clusters: Implications for prediction, prevention, and treatment.
        
        Lancet Diabet. Endocrinol. 11, 426-440 (2023)
    
    
    
				Among 20 leading global risk factors for years of life lost in 2040, reference forecasts point to three metabolic risks-high blood pressure, high BMI, and high fasting plasma glucose-as being the top risk variables. Building upon these and other risk factors, the concept of metabolic health is attracting much attention in the scientific community. It focuses on the aggregation of important risk factors, which allows the identification of subphenotypes, such as people with metabolically unhealthy normal weight or metabolically healthy obesity, who strongly differ in their risk of cardiometabolic diseases. Since 2018, studies that used anthropometrics, metabolic characteristics, and genetics in the setting of cluster analyses proposed novel metabolic subphenotypes among patients at high risk (eg, those with diabetes). The crucial point now is whether these subphenotyping strategies are superior to established cardiometabolic risk stratification methods regarding the prediction, prevention, and treatment of cardiometabolic diseases. In this Review, we carefully address this point and conclude, firstly, regarding cardiometabolic risk stratification, in the general population both the concept of metabolic health and the cluster approaches are not superior to established risk prediction models. However, both subphenotyping approaches might be informative to improve the prediction of cardiometabolic risk in subgroups of individuals, such as those in different BMI categories or people with diabetes. Secondly, the applicability of the concepts by treating physicians and communication of the cardiometabolic risk with patients is easiest using the concept of metabolic health. Finally, the approaches to identify cardiometabolic risk clusters in particular have provided some evidence that they could be used to allocate individuals to specific pathophysiological risk groups, but whether this allocation is helpful for prevention and treatment still needs to be determined.
			
			
		Impact Factor
					Scopus SNIP
					Web of Science
Times Cited
					Times Cited
Scopus
Cited By
					
					Cited By
Altmetric
					
				44.500
					0.000
					15
					4
					
					
				Anmerkungen
				
					
						 
						
					
				
			
				
			
				Besondere Publikation
				
					
						 
					
				
			
			
			
				Auf Hompepage verbergern
				
					
						 
					
				
			
			
        Publikationstyp
        Artikel: Journalartikel
    
 
    
        Dokumenttyp
        Review
    
 
     
    
    
        Schlagwörter
        Unhealthy Normal-weight; Fasting Plasma-glucose; Coronary-heart-disease; Type-2 Diabetes Risk; Cardiovascular-disease; Life-style; Obesity; Metaanalysis; Individuals; Complications
    
 
     
    
    
        Sprache
        englisch
    
 
    
        Veröffentlichungsjahr
        2023
    
 
     
    
        HGF-Berichtsjahr
        2023
    
 
    
    
        ISSN (print) / ISBN
        2213-8587
    
 
    
        e-ISSN
        2213-8595
    
 
     
     
     
	     
	 
	 
    
        Zeitschrift
        Lancet Diabetes and Endocrinology
    
 
		
    
        Quellenangaben
        
	    Band: 11,  
	    Heft: 6,  
	    Seiten: 426-440 
	    
	    
	
    
 
  
         
        
            Verlag
            Elsevier
        
 
        
            Verlagsort
            Ste 800, 230 Park Ave, New York, Ny 10169 Usa
        
 
	
         
         
         
         
         
	
         
         
         
    
         
         
         
         
         
         
         
    
        Begutachtungsstatus
        Peer reviewed
    
 
     
    
        POF Topic(s)
        90000 - German Center for Diabetes Research
    
 
    
        Forschungsfeld(er)
        Helmholtz Diabetes Center
    
 
    
        PSP-Element(e)
        G-502400-001
    
 
    
        Förderungen
        
German Federal Ministry of Education and Research
European Innovative Medicines Initiative SOPHIA
German Research Foundation
 
     	
    
    German Federal Ministry of Education and Research
European Innovative Medicines Initiative SOPHIA
German Research Foundation
        WOS ID
        001053565000001
    
    
        Scopus ID
        85159941849
    
    
        PubMed ID
        37156256
    
    
        Erfassungsdatum
        2023-10-06